<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714763</url>
  </required_header>
  <id_info>
    <org_study_id>DD2RN-2018</org_study_id>
    <nct_id>NCT03714763</nct_id>
  </id_info>
  <brief_title>Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)</brief_title>
  <official_title>The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of Nonfunctioning Pituitary Adenoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhebao Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma
      and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic
      effect of dopamine agonists（DA）.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dopamine agonists are the first line therapy for prolactinoma,which are also effective in
      some cases of other subtypes of pituitary tumors. It had been showed that dopamine agonists
      inhibit prolactin secretion by binding to and activating dopamine D2 receptors. PET-MR
      combined MR images with PET function images is substantial to evaluate the expression of
      dopamine D2 receptors.The aim is to study the in vivo expression of dopamine D2 receptors in
      prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the
      therapeutic effect of dopamine agonists.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline on tumor volume</measure>
    <time_frame>Up to 6 months]</time_frame>
    <description>Change from baseline on tumor volume measured by enhanced pituitary Magnetic Resonance Imaging（MRI）.
Record the tumor volume from enhanced pituitary MRI on every 3 month follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of visual acuity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Record the Visual acuity on every 3 month follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from visual field scale</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>2.Record the Visual field scale on every 3 month follow-up visit, 0 = normal, no vision loss; 1 = one quadrant vision loss; 2 = two quadrants of vision loss; 3 = three quadrants of vision loss; 4 = four quadrants of vision loss but retain a central tubular vision; 5 = blind</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pituitary Adenoma</condition>
  <arm_group>
    <arm_group_label>Drug treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug treatment</intervention_name>
    <description>Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.</description>
    <arm_group_label>Drug treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Normal serum pituitary hormone levels or mild increase of serum prolactin.

          2. Enhanced MRI shows a pituitary tumor and tumor diameter&gt;1cm.

          3. Aged between 18 and 65 years old, either sex.

          4. Karnofsky performance status ≥ 70.

          5. The patient has signed the informed consent.

        Exclusion Criteria:

          1. Patients concomitantly taking the psychotropic drugs.

          2. Patients with parkinson disease and is taking dopaminergic agents.

          3. Patients with pituitary adenoma who received Gamma knife treatment.

          4. Pregnant or lactating women.

          5. Patients with poor compliance, who cannot implement the program strictly.

          6. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to cabergoline.

          7. Patients with claustrophobia. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weiting Gu, MD</last_name>
    <phone>0086-13917778956</phone>
    <email>nowaiting1221@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhebao Wu, Medical PhD</last_name>
    <phone>0086-021-64370045</phone>
    <email>zhebaowu@aliyun.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Mukherjee J, Majji D, Kaur J, Constantinescu CC, Narayanan TK, Shi B, Nour MT, Pan ML. PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents. Synapse. 2017 Mar;71(3). doi: 10.1002/syn.21950. Epub 2016 Nov 30.</citation>
    <PMID>27864853</PMID>
  </results_reference>
  <results_reference>
    <citation>Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):447-60. doi: 10.1016/j.beem.2012.01.002. Epub 2012 May 22. Review.</citation>
    <PMID>22863387</PMID>
  </results_reference>
  <results_reference>
    <citation>Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008 Dec;15(4):905-15. doi: 10.1677/ERC-08-0181. Epub 2008 Sep 9. Review.</citation>
    <PMID>18780796</PMID>
  </results_reference>
  <results_reference>
    <citation>Su Z, Wang C, Wu J, Jiang X, Chen Y, Chen Y, Zheng W, Zhuge Q, Wu Z, Zeng Y. Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas. Neurol Sci. 2012 Apr;33(2):275-9. doi: 10.1007/s10072-011-0701-6. Epub 2011 Jul 12.</citation>
    <PMID>21748460</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhebao Wu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Nonfunctioning Pituitary Adenoma</keyword>
  <keyword>Dopamine Agonist</keyword>
  <keyword>Dopamine D2 Receptors</keyword>
  <keyword>PET-MR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual patient Data would not be shared to the third facility, but the sponsor hasn't decided whether to share the individual patient date to the other related studies hold by himself in the future.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

